Industry Supported Sessions

The Journey of Interleukin-6 Blocking Therapy for autoimmune diseases

SYMPOSIUM IS ORGANISED AND SUPPORTED BY CHUGAI

Wednesday, May 20 | 15:30-17:30 | Hall 3 – Nikos Skalkotas
Chair: Takao Koike, Kazuhiko Yamamoto

15:30-15:40

Opening Remarks

15:40-16:10

New predictor for tocilizumab Treatment on rheumatoid arthritis

16:10-16:45

The Challenging of large vessel vasculitis treatment with tocilizumab

16:45-17:20

New Indication with IL-6 blocking therapy in autoimmune disease

Closing Remarks

SYMPOSIUM IS ORGANISED AND SUPPORTED BY Boehringer Ingelheim

Thursday, May 21 | 12:45-13:45 | Hall 3 – Nikos Skalkotas

Chair: Yannick Allanore, France

12:45-12:50

Welcome and introduction

12:50–13:00

13:00–13:10

13:10–13:20

SSc-ILD: The archetype of lung involvement in autoimmune rheumatic diseases

New paradigms in the management of autoimmune rheumatic disease-related ILDs

Unraveling the pathogenesis of lung fibrosis in autoimmune rheumatic diseases

Non-SSc autoimmune rheumatic diseases: What to look for in the lung and why

Panel Discussion